Is dacomitinib included in medical insurance?

Dacomitinib (Dacomitinib) The original drug has been marketed in China and has entered the scope of Class B medical insurance through the relevant regulations of the National Medical Insurance Administration, but it is only reimbursed for patients who meet the indications, that is, up to Cotinib is used as a single agent for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion mutation or exon 21 L858R substitution mutation.

Dacomitinib is only available by prescription, and treatment must be initiated and supervised by a physician experienced in using cancer drugs. Appropriate testing should be done to confirm the presence of a mutation in the EGFR gene before starting treatment. Dacomitinib has been shown to be more effective than gefitinib, another drug used to treat non-small cell lung cancer, in prolonging patients' survival without their disease worsening. In a major study involving 452 patients with EGFR mutations, those taking dacomitinib lived an average of about 15 months without their disease worsening, compared with an average of nine months for those taking gefitinib.

The domestically marketed dacomitinib original drug, common specifications15mg*30 tablets, may cost more than 1,000 yuan per box; the European version of dacominib original drug sold overseas, specifications45mg*30 tablets may cost more than 20,000 yuan per box (the price may fluctuate due to exchange rates). Currently, there are cheaper generic drugs of dacomitinib sold overseas. Their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 45mg*30 tablets produced by a Lao pharmaceutical factory may be around a few hundred yuan per box (the price may fluctuate due to exchange rate effects).